On July 19th, Gelunhui reported that Shenzhen Chipscreen Biosciences (688321.SH) announced that its wholly-owned subsidiary Chengdu Chipscreen Pharmaceutical Co., Ltd. (referred to as'Chengdu Chipscreen') received the 'Drug Registration Certificate' issued by the National Medical Products Administration, approving Chengdu Chipscreen's application for adding indications for sitagliptin tablets. The new indication is 'used in combination with metformin hydrochloride: when metformin hydrochloride alone is ineffective in controlling blood sugar, this product can be used in combination with metformin hydrochloride to improve blood sugar control in adult patients with type 2 diabetes mellitus, in combination with diet and exercise'.
Indication: Used in combination with metformin hydrochloride: when metformin hydrochloride alone is ineffective in controlling blood sugar, this product can be used in combination with metformin hydrochloride to improve blood sugar control in adult patients with type 2 diabetes mellitus, in combination with diet and exercise.